Blood Brain Barrier Penetration and Pharmacokinetics of the Elemene in Malignant Patients.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01679847

Enrollment

Registered

2012-09-06

Start date

2012-09-30

Completion date

2013-06-30

Last updated

2012-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

Elemene, pharmacokinetics, Blood-brain barrier

Brief summary

The purpose of this study is to elucidate the pharmacokinetics and the blood-brain barrier penetration of the elemene.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* histopathological or cytopathology diagnosis of malignancy * heart, liver and renal function is normal * Expected survival time is more than 3 months * Signed informed consent

Exclusion criteria

* non cancer patient * accepted elemene administration in 1 month * Expected survival time is less than 3 months * no Signed informed consent * heart, liver and renal function is abnormal

Design outcomes

Primary

Measure	Time frame
blood and cerebrospinal fluid concentration	0，0.25，0.5，1，1.5，2，3，3.5，4，6，8，12 hours post dose

Countries

China

Contacts

Primary ContactZHAN QIONG, MD

zjoan2121@gmail.com8621-52887162

Outcome results